{"title":"眼附件黏膜相关淋巴组织淋巴瘤对鹦鹉热衣原体根除难治的补救性放射治疗","authors":"Elena Flospergher MD , Marianna Sassone MD , Anna Chiara MD , Fabrizio Marino MD , Antonio Giordano Resti MD , Maurilio Ponzoni MD , Maria Giulia Cangi MD , Lucia Bongiovanni MD , Gilda Magliacane MD , Giulio Modorati MD , Elisabetta Miserocchi MD , Teresa Calimeri MD, PhD , Piera Angelillo MD , Federico Erbella MD , Andrés J.M. Ferreri MD","doi":"10.1016/j.adro.2025.101822","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>Prospective trials show that <em>Chlamydia psittaci (Cp)</em> eradication with doxycycline is followed by lymphoma regression in 2-thirds of patients with ocular adnexal marginal zone lymphoma (OAMZL). Postponing orbit irradiation, a standard treatment for OAMZL, while waiting for the tumor response to antibiotic, could raise concern. Herein, we report the safety and efficacy of salvage radiation therapy in patients with OAMZL relapsed after or refractory to <em>Cp</em> eradication.</div></div><div><h3>Methods and Materials</h3><div>Patients with stage IEA OAMZL diagnosed at our institution between 2005 and 2023 were evaluated for the safety and efficacy of radiation therapy as salvage treatment after doxycycline. Inclusion criteria were as follows: (1) first-line <em>Cp</em>-eradicating therapy with doxycycline; (2) lymphoma relapsed or progressed locally; and (3) orbital irradiation as salvage treatment.</div></div><div><h3>Results</h3><div>A total of 28 patients (median age 66 years; range, 37-92; 16 males) were assessable; all patients but 2 (relapsing after partial response) experienced progressive disease during or after doxycycline (median 9 months; IQR, 4-40). Radiation therapy (30-36 Gy in 15-18 fractions) was well tolerated, with only 3 cases of grade-2 cataract and 3 cases of grade-1 blepharitis; all irradiated patients achieved a lymphoma regression (overall response rate = 100%), with a complete response rate of 89% (95% CI, 80%-97%). At a median follow-up of 60 months (range, 12-166) from radiation therapy, 8 patients experienced relapse, within the irradiated volume only in 2 (7%), with a 4-year progression-free survival of 74% (95% CI, 72%-75%). All patients but one are alive at a median follow-up from initial lymphoma diagnosis of 96 (IQR, 47-128) months; 22 (79%) patients are disease free.</div></div><div><h3>Conclusions</h3><div>The postponing of orbit irradiation until relapse/progression after <em>Cp</em>-eradicating antibiotic therapy is a safe and effective strategy in patients with limited-stage OAMZL. The vast majority of patients with OAMZL can be safely managed without chemotherapeutic agents, and radiation therapy can be delayed until relapse without affecting patients’ survival.</div></div>","PeriodicalId":7390,"journal":{"name":"Advances in Radiation Oncology","volume":"10 9","pages":"Article 101822"},"PeriodicalIF":2.7000,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Salvage Irradiation for Ocular Adnexal Mucosa Associated Lymphoid Tissue Lymphoma Refractory to Chlamydia psittaci Eradication\",\"authors\":\"Elena Flospergher MD , Marianna Sassone MD , Anna Chiara MD , Fabrizio Marino MD , Antonio Giordano Resti MD , Maurilio Ponzoni MD , Maria Giulia Cangi MD , Lucia Bongiovanni MD , Gilda Magliacane MD , Giulio Modorati MD , Elisabetta Miserocchi MD , Teresa Calimeri MD, PhD , Piera Angelillo MD , Federico Erbella MD , Andrés J.M. Ferreri MD\",\"doi\":\"10.1016/j.adro.2025.101822\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Purpose</h3><div>Prospective trials show that <em>Chlamydia psittaci (Cp)</em> eradication with doxycycline is followed by lymphoma regression in 2-thirds of patients with ocular adnexal marginal zone lymphoma (OAMZL). Postponing orbit irradiation, a standard treatment for OAMZL, while waiting for the tumor response to antibiotic, could raise concern. Herein, we report the safety and efficacy of salvage radiation therapy in patients with OAMZL relapsed after or refractory to <em>Cp</em> eradication.</div></div><div><h3>Methods and Materials</h3><div>Patients with stage IEA OAMZL diagnosed at our institution between 2005 and 2023 were evaluated for the safety and efficacy of radiation therapy as salvage treatment after doxycycline. Inclusion criteria were as follows: (1) first-line <em>Cp</em>-eradicating therapy with doxycycline; (2) lymphoma relapsed or progressed locally; and (3) orbital irradiation as salvage treatment.</div></div><div><h3>Results</h3><div>A total of 28 patients (median age 66 years; range, 37-92; 16 males) were assessable; all patients but 2 (relapsing after partial response) experienced progressive disease during or after doxycycline (median 9 months; IQR, 4-40). Radiation therapy (30-36 Gy in 15-18 fractions) was well tolerated, with only 3 cases of grade-2 cataract and 3 cases of grade-1 blepharitis; all irradiated patients achieved a lymphoma regression (overall response rate = 100%), with a complete response rate of 89% (95% CI, 80%-97%). At a median follow-up of 60 months (range, 12-166) from radiation therapy, 8 patients experienced relapse, within the irradiated volume only in 2 (7%), with a 4-year progression-free survival of 74% (95% CI, 72%-75%). All patients but one are alive at a median follow-up from initial lymphoma diagnosis of 96 (IQR, 47-128) months; 22 (79%) patients are disease free.</div></div><div><h3>Conclusions</h3><div>The postponing of orbit irradiation until relapse/progression after <em>Cp</em>-eradicating antibiotic therapy is a safe and effective strategy in patients with limited-stage OAMZL. The vast majority of patients with OAMZL can be safely managed without chemotherapeutic agents, and radiation therapy can be delayed until relapse without affecting patients’ survival.</div></div>\",\"PeriodicalId\":7390,\"journal\":{\"name\":\"Advances in Radiation Oncology\",\"volume\":\"10 9\",\"pages\":\"Article 101822\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2025-06-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in Radiation Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2452109425001095\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Radiation Oncology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2452109425001095","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
Salvage Irradiation for Ocular Adnexal Mucosa Associated Lymphoid Tissue Lymphoma Refractory to Chlamydia psittaci Eradication
Purpose
Prospective trials show that Chlamydia psittaci (Cp) eradication with doxycycline is followed by lymphoma regression in 2-thirds of patients with ocular adnexal marginal zone lymphoma (OAMZL). Postponing orbit irradiation, a standard treatment for OAMZL, while waiting for the tumor response to antibiotic, could raise concern. Herein, we report the safety and efficacy of salvage radiation therapy in patients with OAMZL relapsed after or refractory to Cp eradication.
Methods and Materials
Patients with stage IEA OAMZL diagnosed at our institution between 2005 and 2023 were evaluated for the safety and efficacy of radiation therapy as salvage treatment after doxycycline. Inclusion criteria were as follows: (1) first-line Cp-eradicating therapy with doxycycline; (2) lymphoma relapsed or progressed locally; and (3) orbital irradiation as salvage treatment.
Results
A total of 28 patients (median age 66 years; range, 37-92; 16 males) were assessable; all patients but 2 (relapsing after partial response) experienced progressive disease during or after doxycycline (median 9 months; IQR, 4-40). Radiation therapy (30-36 Gy in 15-18 fractions) was well tolerated, with only 3 cases of grade-2 cataract and 3 cases of grade-1 blepharitis; all irradiated patients achieved a lymphoma regression (overall response rate = 100%), with a complete response rate of 89% (95% CI, 80%-97%). At a median follow-up of 60 months (range, 12-166) from radiation therapy, 8 patients experienced relapse, within the irradiated volume only in 2 (7%), with a 4-year progression-free survival of 74% (95% CI, 72%-75%). All patients but one are alive at a median follow-up from initial lymphoma diagnosis of 96 (IQR, 47-128) months; 22 (79%) patients are disease free.
Conclusions
The postponing of orbit irradiation until relapse/progression after Cp-eradicating antibiotic therapy is a safe and effective strategy in patients with limited-stage OAMZL. The vast majority of patients with OAMZL can be safely managed without chemotherapeutic agents, and radiation therapy can be delayed until relapse without affecting patients’ survival.
期刊介绍:
The purpose of Advances is to provide information for clinicians who use radiation therapy by publishing: Clinical trial reports and reanalyses. Basic science original reports. Manuscripts examining health services research, comparative and cost effectiveness research, and systematic reviews. Case reports documenting unusual problems and solutions. High quality multi and single institutional series, as well as other novel retrospective hypothesis generating series. Timely critical reviews on important topics in radiation oncology, such as side effects. Articles reporting the natural history of disease and patterns of failure, particularly as they relate to treatment volume delineation. Articles on safety and quality in radiation therapy. Essays on clinical experience. Articles on practice transformation in radiation oncology, in particular: Aspects of health policy that may impact the future practice of radiation oncology. How information technology, such as data analytics and systems innovations, will change radiation oncology practice. Articles on imaging as they relate to radiation therapy treatment.